Secondary Logo

Share this article on:

Complex regional pain syndrome–up-to-date

Birklein, Frank*; Dimova, Violeta

doi: 10.1097/PR9.0000000000000624
PAIN Clinical Updates

Complex regional pain syndrome (CRPS) was described for the first time in the 19th century by Silas Weir Mitchell. After the exclusion of other causes, CRPS is characterised by a typical clinical constellation of pain, sensory, autonomic, motor, or trophic symptoms which can no longer be explained by the initial trauma. These symptoms spread distally and are not limited to innervation territories. If CRPS is not improved in the acute phase and becomes chronic, the visible symptoms change throughout because of the changing pathophysiology; the pain, however, remains. The diagnosis is primarily clinical, although in complex cases further technical examination mainly for exclusion of alternative diagnoses is warranted. In the initial phase, the pathophysiology is dominated by a posttraumatic inflammatory reaction by the activation of the innate and adaptive immune system. In particular, without adequate treatment, central nociceptive sensitization, reorganisation, and implicit learning processes develop, whereas the inflammation moderates. The main symptoms then include movement disorders, alternating skin temperature, sensory loss, hyperalgesia, and body perception disturbances. Psychological factors such as posttraumatic stress or pain-related fear may impact the course and the treatability of CRPS. The treatment should be ideally adjusted to the pathophysiology. Pharmacological treatment maybe particularly effective in acute stages and includes steroids, bisphosphonates, and dimethylsulfoxide cream. Common anti-neuropathic pain drugs can be recommended empirically. Intravenous long-term ketamine administration has shown efficacy in randomised controlled trials, but its repeated application is demanding and has side effects. Important components of the treatment include physio- and occupational therapy including behavioural therapy (eg, graded exposure in vivo and graded motor imaging). If psychosocial comorbidities exist, patients should be appropriately treated and supported. Invasive methods should only be used in specialised centres and in carefully evaluated cases. Considering these fundamentals, CRPS often remains a chronic pain disorder but the devastating cases should become rare.

The pathophysiology of complex regional pain syndromes includes inflammation and central reorganisation. The treatment should be adjusted to the prevailing pathophysiology including possible psychosocial factors.

Department of Neurology, University Medical Centre of the Johannes Gutenberg University Mainz, Mainz, Germany

Corresponding author. Address: Department of Neurology, University Medical Centre of the Johannes Gutenberg University Mainz, Langenbeckstraße 1, 55101 Mainz, Germany. Tel.: +49-6131-173270. E-mail address: frank.birklein@unimedizin-mainz.de (F. Birklein).

Sponsorships or competing interests that may be relevant to content are disclosed at the end of this article.

This is an open access article distributed under the Creative Commons Attribution License 4.0 (CCBY), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Received June 30, 2017

Received in revised form August 11, 2017

Accepted August 28, 2017

Back to Top | Article Outline

Key Points

The pathophysiology of complex regional pain syndrome has become clearer through research in recent years. The pathophysiology translates into clinical symptoms, which can be identified. Treatment should be individually tailored according to the predominant pathophysiology. This is outlined in this article.

Back to Top | Article Outline

1. The history of complex regional pain syndrome

It took approximately 100 years to form the acronym “CRPS.” In 1864, Silas Weir Mitchell reported on patients whose disease corresponds to what we now call complex regional pain syndrome (CRPS) type II (Causalgia).61 In 1901, Paul Sudeck from Hamburg, Germany, described the “acute reflex bone atrophy after inflammation and injuries of the extremities and their clinical appearances,” which corresponds to CRPS type I without nerve lesion.87 The next milestone in CRPS history was reached in 1936, when James A. Evans coined the phrase “reflex sympathetic dystrophy”, which has been used for decades.31 At a conference in Orlando, 1995, it was agreed to use the descriptive phrase “Complex Regional Pain Syndrome” to avoid claims about pathophysiology.86

Back to Top | Article Outline

2. Principal factors for development and prognosis

Complex regional pain syndrome usually develops after an injury of the extremities. The latency between the injury and the earliest CRPS diagnosis depends on the “normal” time of recovery from injury. For an uncomplicated radial fracture, a recovery of 4 to 6 weeks is typically realistic. Complicated injuries take longer to recover. Thereafter, a diagnosis of CRPS could be made (point 1 of the diagnostic criteria; see below). Women aged between 40 and 60 seem to be most frequently affected. The female preponderance, however, could also be an artefact because women suffer 3 times more radial fractures than men.45

The risk of CRPS seems to be higher for patients with complicated fractures, a rheumatological disease, or intense pain (>5 on a 11-point numerical rating scale) 1 week after trauma.65,84 Epidemiological data from 2 major studies show a CRPS incidence between 5.577 and 26.2 cases25 per 100,000 people per year. The variation may result from the use of different diagnostic criteria. It is only in the last decade that the validated “Budapest Criteria” (see below) have become generally accepted.

Regarding the prognosis, Bean et al reported in a longitudinal study that within the first year, 70% improved, especially in the function of the extremity and the visible symptoms (edema, skin color, and sweating). However, 25% of the patients still fulfilled the Budapest Criteria and only 5% were without complaints.5,8 Patients reporting higher levels of anxiety and pain-related fear at the beginning of therapy have worse long-term outcomes after 1 year.6

Back to Top | Article Outline

3. Classification and diagnosis

The diagnosis of CRPS is made clinically using the diagnostic criteria of the “IASP”38 (Table 1). It can be differentiated between CRPS type I, without obvious nerve lesion and CRPS type II, with verifiable nerve lesion. At first presentation, approximately 70% of patients report about a “primarily warm” subtype with an increased skin temperature at symptom onset, whereas the remaining 30% report a “primarily cold” subtype.13 Typically, a trauma precedes the clinical symptoms; “spontaneous” CRPS is rare and needs an extensive clarification of differential diagnoses because it is important to notice point 4 of the diagnostic criteria: “There is no other diagnosis that better explains the symptoms.” Unfortunately, the fact that CRPS usually affects distal limbs (an exception might be the knee) is not mentioned and neither is the fact that the signs must go beyond single-nerve innervation territories. Despite case reports, the authors doubt that CRPS of large joints, face, or trunk exists.

Table 1

Table 1

Instrument-based investigations might be beneficial if there are doubts concerning the differential diagnoses. (1) Repeated measurements of the skin temperature show dynamics, ie, changing temperature differences (warmer gets colder or vice versa) of >1°C51; (2) Limb magnetic resonance imaging helps to exclude differential diagnoses like rheumatic diseases or infections; (3) x-rays in direct side-to-side comparison are not sensitive but can prove a patchy osteoporosis or may help to make differential diagnoses such as a pseudoarthrosis after fracture; (4) the 3-phase bone technetium scintigraphy in acute (but not chronic) CRPS has a 70% specificity and sensitivity compared to the clinical diagnostic criteria if there is evidence of an increased bone metabolism, typically in distal joints.101

Quantitative sensory testing (QST), which has become important in academic pain medicine, is not suited to make a CRPS diagnosis because QST generally describes pain symptoms (eg, hyperalgesia), which are not specific for any pain disorder. However, a typical QST pattern (thermhypaesthesia, mechanical hyperalgesia, and pressure hyperalgesia) may support a CRPS diagnosis, particularly if the distal joints, which were not directly affected by the trauma, are sensible to pressure pain.57

The CRPS severity score (Table 2)39 might be an instrument to grade the severity of CRPS and helps to monitor the course. Very low scores support considering a differential diagnosis (Table 2).

Table 2

Table 2

Back to Top | Article Outline

4. Clinical symptoms

Pain is the most important symptom. It is permanent or fluctuating and most often in the deep tissue. It increases through movements and during changes in temperature; in the experience of the authors, especially in chronic and severe cases, allodynia is a hallmark.12 At the same time, sensory deficits are reported: hypoesthesia and impairment of thermal perception17 after a glove- or stocking-like pattern. Patients report feelings that their extremity no longer belongs to their body.33 All patients have decreased muscle strength and probably pain-induced movement avoidance.12 Contractures develop quickly. Although the decrease in strength and the inhibition of movement both improve with reduction in pain, contractures improve slowly and sometimes remain permanent. Mainly poorly treated acute (<3–6 months from the onset) CRPS cases might develop shortening and fibrosis of capsules and tendons.100 In some cases, this could happen regardless of any treatment attempt. Other trophic changes can be found on the skin (eg, ulcers), the nails, and the hairs (in acute CRPS increased and in chronic CRPS decreased growth).58 The main symptom of vascular dysfunction is the oedema which can grow to dramatic extents and is always found in the acute phase.12 In chronic CRPS, patients report their own extremity often thicker than it actually is.72 Fifty percent of the patients have sudomotor disturbances, mostly a hyperhidrosis.12 All patients display a change in skin colour from reddish (“warm” CRPS) to blueish livid (“cold” CRPS).11,13 Skin temperature is different when comparing both sides.94 More rare are tremor, myoclonus, or fixed dystonia.93

Back to Top | Article Outline

5. Pathophysiology of complex regional pain syndrome

5.1. Exaggerated inflammation

It is heavily discussed whether there is a genetic disposition for CRPS. There are “CRPS families”42 and striking associations to migraine.74 Associations with known gene polymorphisms have been described in smaller studies but could not be replicated in larger cohorts.44 As long as we do not have biomarkers for subgrouping, the detection of genetic factors will remain difficult. Furthermore, association studies need high numbers, but CRPS is a rare disease. MicroRNAs are “master switches” for complex inflammatory reactions and pain states because they control the translational process for several proteins at the same time. If replicated, the pattern of microRNAs in plasma exosomes for cell–cell communication might be useful to identify patients with CRPS early after a trauma.59

The first step of CRPS pathophysiology is posttraumatic inflammation, mainly in “warm” CRPS, during the acute phase of the disease. Clinical observation finds signs of inflammation like redness, swelling, hyperthermia, pain, and reduced function58 (c.f. Galen, ∼210 A.D.). A trauma causes a complex immune response. In the skin, keratinocytes proliferate and produce inflammatory cytokines as part of the innate immune system.10 The cytokines (from keratinocytes, endothelial or immune cells) themselves proliferate connective tissue cells leading to contractures.9 Cytokines activate osteoblasts and osteoclasts, which explains the osteoporosis.98 Cytokines provoke pain and hyperalgesia through sensitization of peripheral nociceptors, and they facilitate the release of neuropeptides from nociceptors,69 which in turn are responsible for the “visible” inflammatory signs. Calcitonin gene–related peptide and substance P are released from the cytokine-sensitized nociceptors (neurogenic inflammation) and cause reddening, warmth, and edema36,96; substance P further promotes hair growth,71 and calcitonin gene–related peptide enhances sweating.80 Throughout the course of CRPS, most of these signs normalize, which demonstrates some change in pathophysiology.54 Recent investigations suggest a contribution of the adaptive immune system as well. The detection of agonistic serum auto-antibodies against adrenergic and cholinergic receptors renders an auto-immune component of CRPS very likely.30,50 Inflammation is less obvious in primarily cold CRPS, and investigations specifically for this subtype are sparse. Increased endothelin 1 and reduced nitric oxide probably contribute to the cold bluish skin.36 In preclinical studies, we found that a lack of neutral endopeptidase (reduced activity of peptidases is 1 hypothesis for a susceptibility for CRPS after trauma26) increases endothelin-1, which in turn sensitizes C-fibres.41

Back to Top | Article Outline

5.2. Central reorganization

The next step in CRPS pathophysiology is neuronal plasticity in the CNS, which is either induced by inflammation or develops in parallel. Plasticity is important, especially for CRPS, which is treatment resistant for more than 6 to 12 months, when symptoms cannot be explained through peripheral pathophysiology alone. In part, those symptoms can be attributed to learning processes, ie, “learned non-use” because of movement-related pain avoidance.75 Another possibility is a reflex inhibition of movement mediated by the expectation of pain.89 This results in a pathological movement pattern (eg, while walking), which again increases the pain through eg, unphysiological muscle and joint loads.27,55 Other symptoms are a direct consequence of reorganisation of somatosensory function in the brain22,53: body midline is shifted towards the healthy side and the CRPS extremity is perceived as distorted.64 The perception of allodynia is a consequence of central (spinal) sensitization. Its presence has been verified through functional magnetic resonance imaging by activation of the “pain matrix” through painful touching of the affected but not by nonpainful touching of the unaffected hand.56 For details on functional imaging in CRPS, we refer to an upcoming review.88

Back to Top | Article Outline

5.3. Reflex? sympathetic? dystrophy?

The significance of a sympathetic nervous system dysfunction for CRPS development has been questioned. Many of the presumably sympathetic symptoms like edema, vasodilatation, or hyperhidrosis can be explained through inflammation.80,97 However, inflammatory processes fade within the first year. If visible autonomic symptoms (eg, cold bluish skin, edema, and sweating changes) remain, they must have another pathophysiology, eg, sympathetic dysfunction as a consequence of central reorganisation.34 If patients with chronic CRPS think of a movement which would be painful, they activate the sympathetic nervous system.66 The skin temperature minimally changes when crossing over the hands bringing the CRPS hand into the healthy “peripersonal” space.64

In addition, peripheral adrenoreceptors of the affected tissue develop supersensitivity2 supposedly through the inflammatory processes within the first months. This supersensitivity causes activation of the sympathetic nervous system, which is normally symmetrical, leads to asymmetrical sympathetic symptoms. The hypothesis of “sympathetically maintained pain” is similar: nociceptors in the affected limb become sensitive to catecholamines.78 The presumably sympathetic symptoms were the motivations for the use of sympathetic blocks to treat CRPS. However, meta-analyses with inconclusive findings raised doubts.67 Today, sympathetic blocks should be an exception rather than a rule for CRPS treatment.

The role of the recently discovered agonistic auto-antibodies against adreno- and acetylcholine-receptors in the generation of autonomic symptoms or pain is to be clarified in future studies.30,50

Back to Top | Article Outline

5.4. Psychosocial factors

Depression and anxiety, which were assessed by self-reports, are not related to the development of CRPS.7 However, it would be naive to suppose that only in CRPS, on the contrary to all other chronic pain diseases, psychosocial factors would not be involved particularly in perpetuation of pain, suffering, and reduced participation. In comparison to patients with limb pain (10% in limb pain controls and 4% in healthy subjects), 38% of patients with CRPS report posttraumatic stress symptoms after life events before CRPS.85 Patients with CRPS also reported more depersonalization phenomena than limb pain controls on the 29 items Cambridge Depersonalization Scale.60 In CRPS with fixed dystonia, a somatoform movement disorder is expected in more than 25%.81 Anxiety, pain-related fears, and perceived disability are negative predictors for the treatment success after 1 year.6

The research on social factors in CRPS is in its infancy. Surprisingly, it is the affluent patients, who develop CRPS more often after distal radius fracture.21 Because CRPS develops mainly after trauma, it is not surprising that many patients are involved in lawsuits or compensation claims.1,52 Not specifically for CRPS but for “persisting limb pain,” external attributions of responsibility for the injury, and psychological distress were predictors of significant pain 6 months after an orthopaedic trauma in a prospective study. In addition, poor recovery expectations were predictors of pain-related work disability, and being injured at work a predictor of pain severity.20 Furthermore, patients with compensation claims, greater financial worry, and actual or perceived injustice (consulting a lawyer, attributing fault to another, and sustaining compensable injury) led to an increase in the risk of failing to return to work.35 High perceived injustice was correlated to low education and prevented return to work 12 months after injury.43

Back to Top | Article Outline

6. Treatment options

A problem of multi-faceted pathophysiology is that a “one fits all”-treatment for CRPS will probably never be available. Another big problem with CRPS therapy is that high-quality randomized controlled multicentre trials (RCTs) are missing. Most RCTs are single centre or lack an active placebo arm. Furthermore, since the publication of highly recognized negative trials for pain relief through vertebroplasty, which used an adequate control arm,14,47 CRPS intervention studies must be interpreted with care. Nevertheless, treatment options, which were supported by an RCT, are marked by “RCT” in this review. However, the section is influenced by the authors' experiences from 25 years of CRPS care. A systematic approach would have to report mainly “no firm evidence.”68

Because of the above-mentioned constellations in CRPS pathophysiology, the following basic therapeutic principles evolve:

  • (1) Medical and nonmedical pain therapy (acute and chronic phases)
  • (2) Physiotherapy, occupational therapy and training therapy (acute and chronic phases)
  • (3) Anti-inflammatory therapy (acute phase)
  • (4) Psycho- and sociotherapy in a multimodal treatment setting (especially targeting pain-related fears; all phases if necessary)
  • (5) A limited number of sympathetic nerve blocks (in selected cases after successful test blocks, in specialized centres)
  • (6) Therapy of dystonia (only at specialized centres).

In the following, therapeutic recommendations for CRPS are described referring also to the guidelines published by eg, the German Association for Neurology (www.dgn.org./leitlinien.html).

Back to Top | Article Outline

6.1. Medical and nonmedical pain therapy (acute and chronic phases)

There is no firm proof of efficacy in CRPS for drugs used in other chronic neuropathic pain disorders. A very moderate effect on allodynia was shown for gabapentin (RCT; secondary end point).91 It is justified to assume that this might be valid also for pregabalin. Sedative tricyclic antidepressants should be used in particular if sleeping problems prevail. Although there are no controlled studies, analgesic drugs according to the World Health Organization analgesic ladder can be tested, especially in very acute phases. If opioids are chosen,37 we suggest that a clear efficacy (eg, reduction of pain >> 50% with reasonable doses) must be demonstrated within 2 weeks. The efficacy of opioids must be strictly controlled. Otherwise, opioid-insensitive pain leads to false increase of dosage, habituation, dependence, and finally increase in pain (opioid-induced hyperalgesia76). Opioid-insensitive pain might be frequent because of decreased central opioid receptor availability in CRPS.49

There might be a reduction in pain for up to 3 months after intravenous ketamine (continuous infusion for 4 days; maximum 30 mg/h for a 70-kg patient). There are 3 RCTs and many case reports. For the exact protocol, the original publication should be studied.82 We want to indicate that blinding must have been incomplete because of the obligate psychotropic side effects of ketamine (vs saline). Accordingly, most systematic reviews and meta-analyses came to the conclusion of “low quality evidence” for ketamine.23 If treatment courses are repeated, liver and psychiatric side effects must be monitored.

After failure of noninvasive therapies, spinal cord stimulation (SCS) seems to be an alternative to treat CRPS pain but not function in the lower extremity for up to 5 years (RCT, no active control).48 SCS for the upper extremity might be problematic because of complications like dislocations of the electrodes. Equally promising seems the stimulation of dorsal root ganglia (DRG). One controlled study (RCT) has been published in which patients were treated either with DRG stimulation or with SCS.28 The devices were implanted only after positive test stimulations. The outcome of the DRG stimulation regarding pain reduction and quality of life was superior to SCS. Like in all interventions, the outcome is dependent on the surgeon's expertise. Relevant psychological comorbidities must be excluded beforehand. Otherwise, there will be further traumatization70 and reduced efficacy.16

Back to Top | Article Outline

6.2. Anti-inflammatory therapy (acute phase)

Not only in our hands glucocorticoids reduce posttraumatic inflammation.19,100 We have good experiences with the administration of high initial doses of oral glucocorticoid (100 mg prednisolone per day), which is then tapered down by 25 mg every 4 days.100 Under the assumption of an ongoing inflammation for 3 to 6 months,10 higher doses (eg, 500–1000 mg methylprednisolone intravenously as in multiple sclerosis therapy) and longer treatment courses (as in all autoimmune diseases) would make more sense but high-quality randomized controlled trials for steroids are lacking, and therefore we follow the principle of “primum non nocere.” Pathophysiologically, steroids make sense during the acute phase.

Bisphosphonates are drugs which are best investigated for CRPS; there are positive studies (several mainly mono-centre RCTs) for nearly all bisphosphonates available in the market.18 They not only reduce osteoclast activity, but also inhibit posttraumatic inflammation.95 Alendronate is administered either orally with a high dose of 40 mg/d across 8 weeks, or intravenously with a dosage of 7.5 mg for 3 consecutive days. Clondronate is administered intravenously with a dosage of 300 mg for 10 consecutive days; pamindronate with a single dosage of 60 mg, and neridronate 4 times with 100 mg every third day. Whether bisphosphonates are a reasonable treatment only for acute or also for chronic CRPS has to be debated. Pathophysiologically, they make more sense for acute CRPS. We want to make a personal comment. In our hands, bisphosphonates seem to be of limited value in particular after steroid treatment.

In the Netherlands, the application of dimethylsulfoxide 50% as a fatty basis cream—3 times daily on the affected extremity—is a standard procedure. Dimethylsulfoxide traps free radicals, which are produced during inflammation and ischemia. Dimethylsulfoxide had a positive impact on a composite score but not specifically on pain (RCT).73,102

Back to Top | Article Outline

6.3. Physiotherapy/occupational therapy/training therapy (acute and chronic phases)

Physical and occupational therapies accomplish reduction of pathologic movement patterns and movement limitations and train a physiologic use of the extremity. Patients should be encouraged to voluntarily use the affected extremity even if this involves a temporary increase in pain and other symptoms. The safety of such an approach has been demonstrated.90 There is still a widespread misconception that patients with CRPS should avoid pain to prevent an aggravation; this is not valid. If the extremity is not moved during the inflammatory phase when a proliferation of connective tissue cells occurs, contractures follow quickly. On the contrary, painful interventions by others, against the will of the patients, eg, passive movements by therapists or less empathic physicians, should be avoided because of a loss of patients' self-control.

Mirror therapy involves learning to adapt the mirror image of the healthy extremity as the affected limb. This should reduce pain and subsequently improve movement. Mirror therapy works best with acute CRPS and CRPS after stroke (small RCT, only for poststroke CRPS)15 and is a standard procedure for experienced physiotherapists. An advancement of mirror therapy is “graded motor imagery.” Initially, this includes recognition of right and left extremities on a monitor; a second step is the imagination of movements of the affected extremity, and the third step is the mirror therapy itself. Efficacy was high in single-centre studies (RCT)62,63 but not reproduced in an open multi-centre trial, which should usually be even more sensitive to placebo effects.46 “Pain Exposure Physical Therapy” (including passive treatments) is performed with the patients' consent, ignoring pain. Pain is not further mentioned throughout the treatment. In an open study, this approach led to an improvement of function and to an improvement of pain. This effect could not be confirmed in an RCT, drop outs were high.3 In general, meta-analyses came to the conclusion that there is still a lack of high quality studies for these components of CRPS treatment.68

Back to Top | Article Outline

6.4. Psycho- and sociotherapy in a multimodal treatment setting (especially targeting pain-related fears; all phases)

Psychotherapeutic and sociotherapeutic methods represent an important part of multimodal pain therapy, especially if accompanying psychosocial factors or comorbidities exist (eg, depressive mood, pain-related avoidance, posttraumatic stress disorders, perceived injustice, and financial worries).35,83,99 The authors' experiences are that patients with many psychosocial problems seem to be harder to treat. This is not due to the desire for compensation; the reason could be a deep uncertainty regarding future perspectives. This is not beneficial for an active participation in treatment.24,29

“Graded Exposure” (GEXP) treatment has shown good evidence for efficacy in CRPS. For this approach, a psychologist identifies and classifies fear-triggering situations (eg, pain induction through certain movements and situations). Patients are then gradually exposed to these situations by a physiotherapist. The efficacy of graded exposure in comparison to conventional rehabilitative therapy was confirmed in 1 large case series for chronic CRPS (n = 106) and a recently published small and monocentre RCT.29 Graded exposure reduced pain and improved function.

Back to Top | Article Outline

6.5. A limited number of sympathetic nerve blocks (in selected cases after successful test blocks, in specialized centres)

A recent Cochrane analysis could not reveal evidence for the efficacy of sympathetic blocks67 because of the lack of high-quality studies. This means a definite negative assumption is also not possible. In our view and according to consensus of experts, who contributed to the German CRPS treatment guideline, a series of sympathetic blocks under strict control of the therapeutic effect (pain reduction >> 50%) throughout 5 weeks (twice a week) can be tried,4 if a test block in the beginning was successful. Such a series should be prematurely stopped if single blocks became unsuccessful, or conversely, if long-lasting therapeutic effects have been achieved. Sympathetic blocks are not first-line therapy and should only be conducted by an experienced pain therapist.

Back to Top | Article Outline

6.6. Therapy of dystonia (only at specialized centres)

Botulinum toxin might be less effective for treatment of fixed dystonic posturing in CRPS than for action-related dystonia in neurology.79 However, we agree that because of the minimally invasive character, a therapeutic attempt makes sense in selected cases (Fig. 1, clinical diagnostic criteria for CRPS are fulfilled). Our experiences show that dosage and number of treated muscles must be high enough to reduce muscle strength. If botulinum toxin improves dystonia, pain also improves. In case studies, successful treatment of dystonia has been shown during continuous intrathecal application of baclofen by a pump.92 This treatment, however, must be performed by experienced centres and only after vigorous assessment32 including psychological factors.40 Complications like catheter dislocation or break and cerebrospinal fluid leakage with postural headaches are frequent. Firm evidence that both treatments for CRPS dystonia are successful is sparse (Fig. 2).

Figure 1

Figure 1

Figure 2

Figure 2

Back to Top | Article Outline

7. Outlook

Complex regional pain syndrome is a “visible” pain disease. During the past years, there has been significant progress in understanding the pathophysiology, which will ultimately lead to better individualized treatment. It is important to explain the pathophysiology of CRPS as good as we know and the purpose of each therapy to the patients, and to motivate them to actively participate by developing self-management strategies. Thereby, therapeutic success might become better. Whether the treatment success is sufficient to reintegrate patients back into their previous lives also depends on nonmedical factors. In any case, we urgently need multicentre RCTs, which have to be performed by closely cooperating networks.

Back to Top | Article Outline

Disclosures

The authors have no conflict of interest to declare.

The authors were supported by intramural funds of the University Medical Center Mainz to V. Dimova and the Berufsgenossenschaft für das Gesundheitswesen Mainz and the EU, FP7 under grant agreement number 602133 to F. Birklein.

Back to Top | Article Outline

Acknowledgments

The authors thank Ms. Cheryl Ernest and Mr. Josche van der Ven for editorial help.

Back to Top | Article Outline

References

[1]. Allen G, Galer BS, Schwartz L. Epidemiology of complex regional pain syndrome: a retrospective chart review of 134 patients. PAIN 1999;80:539–44.
[2]. Arnold JMO, Teasell RW, MacLeod AP, Brown JE, Carruthers SG. Increased venous alpha-adrenoreceptor responsiveness in patients with reflex sympathetic dystrophy. Ann Int Med 1993;118:619–21.
[3]. Barnhoorn KJ, van de Meent H, van Dongen RT, Klomp FP, Groenewoud H, Samwel H, Nijhuis-van der Sanden MW, Frolke JP, Staal JB. Pain exposure physical therapy (PEPT) compared to conventional treatment in complex regional pain syndrome type 1: a randomised controlled trial. BMJ Open 2015;5:e008283.
[4]. Baron R, Schattschneider J, Binder A, Siebrecht D, Wasner G. Relation between sympathetic vasoconstrictor activity and pain and hyperalgesia in complex regional pain syndromes: a case-control study. Lancet 2002;359:1655–60.
[5]. Bean DJ, Johnson MH, Heiss-Dunlop W, Kydd RR. Extent of recovery in the first 12 months of complex regional pain syndrome type-1: a prospective study. Eur J Pain 2016;20:884–94.
[6]. Bean DJ, Johnson MH, Heiss-Dunlop W, Lee AC, Kydd RR. Do psychological factors influence recovery from complex regional pain syndrome type 1? A prospective study. PAIN 2015;156:2310–18.
[7]. Beerthuizen A, Stronks DL, Huygen FJ, Passchier J, Klein J, Spijker AV. The association between psychological factors and the development of complex regional pain syndrome type 1 (CRPS1)—a prospective multicenter study. Eur J Pain 2012;15:971–75.
[8]. Beerthuizen A, Stronks DL, Van't Spijker A, Yaksh A, Hanraets BM, Klein J, Huygen FJPM. Demographic and medical parameters in the development of complex regional pain syndrome type 1 (CRPS1): prospective study on 596 patients with a fracture. PAIN 2012;153:1187–92.
[9]. Bianchi E, Taurone S, Bardella L, Signore A, Pompili E, Sessa V, Chiappetta C, Fumagalli L, Di Gioia C, Pastore FS, Scarpa S, Artico M. Involvement of pro-inflammatory cytokines and growth factors in the pathogenesis of Dupuytren's contracture: a novel target for a possible future therapeutic strategy? Clin Sci (Lond) 2015;129:711–20.
[10]. Birklein F, Drummond PD, Li W, Schlereth T, Albrecht N, Finch PM, Dawson LF, Clark JD, Kingery WS. Activation of cutaneous immune responses in complex regional pain syndrome. J Pain 2014;15:485–95.
[11]. Birklein F, Riedl B, Claus D, Neundörfer B. Pattern of autonomic dysfunction in time course of complex regional pain syndrome. Clin Aut Res 1998;8:79–85.
[12]. Birklein F, Riedl B, Sieweke N, Weber M, Neundorfer B. Neurological findings in complex regional pain syndromes—analysis of 145 cases. Acta Neurol Scand 2000;101:262–9.
[13]. Bruehl S, Maihofner C, Stanton-Hicks M, Perez RS, Vatine JJ, Brunner F, Birklein F, Schlereth T, Mackey S, Mailis-Gagnon A, Livshitz A, Harden RN. Complex regional pain syndrome: evidence for warm and cold subtypes in a large prospective clinical sample. PAIN 2016;157:1674–81.
[14]. Buchbinder R, Osborne RH, Ebeling PR, Wark JD, Mitchell P, Wriedt C, Graves S, Staples MP, Murphy B. A randomized trial of vertebroplasty for painful osteoporotic vertebral fractures. N Engl J Med 2009;361:557–68.
[15]. Cacchio A, De Blasis E, Necozione S, di Orio F, Santilli V. Mirror therapy for chronic complex regional pain syndrome type 1 and stroke. N Engl J Med 2009;361:634–6.
[16]. Campbell CM, Jamison RN, Edwards RR. Psychological screening/phenotyping as predictors for spinal cord stimulation. Curr Pain Headache Rep 2013;17:307.
[17]. Caty G, Hu L, Legrain V, Plaghki L, Mouraux A. Psychophysical and electrophysiological evidence for nociceptive dysfunction in complex regional pain syndrome. PAIN 2013;154:2521–8.
[18]. Chevreau M, Romand X, Gaudin P, Juvin R, Baillet A. Bisphosphonates for treatment of Complex Regional Pain Syndrome type 1: a systematic literature review and meta-analysis of randomized controlled trials versus placebo. Joint Bone Spine 2017;84:393–9.
[19]. Christensen K, Jensen EM, Noer I. The reflex sympathetic dystrophy syndrome; response to treatment with systemic corticosteroids. Acta Chir Scand 1982;148:653–5.
[20]. Clay FJ, Newstead SV, Watson WL, Ozanne-Smith J, Guy J, McClure RJ. Bio-psychosocial determinants of persistent pain 6 months after non-life-threatening acute orthopaedic trauma. J Pain 2010;11:420–30.
[21]. Clement ND, Duckworth AD, Wickramasinghe NR, Court-Brown CM, McQueen MM. Does socioeconomic status influence the epidemiology and outcome of distal radial fractures in adults? Eur J Orthop Surg Traumatol 2017. [epub ahead of print] doi: .
[22]. Cohen H, McCabe C, Harris N, Hall J, Lewis J, Blake DR. Clinical evidence of parietal cortex dysfunction and correlation with extent of allodynia in CRPS type 1. Eur J Pain 2013;17:527–38.
[23]. Connolly SB, Prager JP, Harden RN. A systematic review of ketamine for complex regional pain syndrome. Pain Med 2015;16:943–69.
[24]. de Jong JR, Vlaeyen JW, Onghena P, Cuypers C, den Hollander M, Ruijgrok J. Reduction of pain-related fear in complex regional pain syndrome type I: the application of graded exposure in vivo. PAIN 2005;116:264–75.
[25]. de Mos M, De Bruijn AG, Huygen FJ, Dieleman JP, Stricker BH, Sturkenboom MC. The incidence of complex regional pain syndrome: a population-based study. PAIN 2007;129:12–20.
[26]. de Mos M, Huygen FJ, Stricker BH, Dieleman JP, Sturkenboom MC. The association between ACE inhibitors and the complex regional pain syndrome: suggestions for a neuro-inflammatory pathogenesis of CRPS. PAIN 2009;142:218–24.
[27]. Debi R, Mor A, Segal G, Debbi EM, Cohen MS, Igolnikov I, Bar Ziv Y, Benkovich V, Bernfeld B, Rozen N, Elbaz A. Differences in gait pattern parameters between medial and anterior knee pain in patients with osteoarthritis of the knee. Clin Biomech (Bristol, Avon) 2012;27:584–7.
[28]. Deer TR, Levy RM, Kramer J, Poree L, Amirdelfan K, Grigsby E, Staats P, Burton AW, Burgher AH, Obray J, Scowcroft J, Golovac S, Kapural L, Paicius R, Kim C, Pope J, Yearwood T, Samuel S, McRoberts WP, Cassim H, Netherton M, Miller N, Schaufele M, Tavel E, Davis T, Davis K, Johnson L, Mekhail N. Dorsal root ganglion stimulation yielded higher treatment success rate for CRPS and causalgia at 3 and 12 months: randomized comparative trial. PAIN 2017;158:669–81.
[29]. den Hollander M, Goossens M, de Jong J, Ruijgrok J, Oosterhof J, Onghena P, Smeets R, Vlaeyen JW. Expose or protect? A randomized controlled trial of exposure in vivo vs pain-contingent treatment as usual in patients with complex regional pain syndrome type 1. PAIN 2016;157:2318–29.
[30]. Dubuis E, Thompson V, Leite MI, Blaes F, Maihofner C, Greensmith D, Vincent A, Shenker N, Kuttikat A, Leuwer M, Goebel A. Longstanding complex regional pain syndrome is associated with activating autoantibodies against alpha-1a adrenoceptors. PAIN 2014;155:2408–17.
[31]. Evans JA. Reflex sympathetic dystrophy. Surg Clin North Am 1946;26:780–90.
[32]. Frei KP, Pathak M, Jenkins S, Truong DD. Natural history of posttraumatic cervical dystonia. Mov Disord 2004;19:1492–8.
[33]. Galer BS, Butler S, Jensen MP. Case reports and hypothesis: a neglect-like syndrome may be responsible for the motor disturbance in reflex sympathetic dystrophy (complex regional pain syndrome-1). J Pain Symptom Manage 1995;10:385–92.
[34]. Geha PY, Baliki MN, Harden RN, Bauer WR, Parrish TB, Apkarian AV. The brain in chronic CRPS pain: abnormal gray-white matter interactions in emotional and autonomic regions. Neuron 2008;60:570–81.
[35]. Giummarra MJ, Cameron PA, Ponsford J, Ioannou L, Gibson SJ, Jennings PA, Georgiou-Karistianis N. Return to work after traumatic injury: increased work-related disability in injured persons receiving financial compensation is mediated by perceived injustice. J Occup Rehabil 2017;27:173–85.
[36]. Groeneweg JG, Huygen FJ, Heijmans-Antonissen C, Niehof S, Zijlstra FJ. Increased endothelin-1 and diminished nitric oxide levels in blister fluids of patients with intermediate cold type complex regional pain syndrome type 1. BMC Musculoskelet Disord 2006;7:91.
[37]. Gustin SM, Schwarz A, Birbaumer N, Sines N, Schmidt AC, Veit R, Larbig W, Flor H, Lotze M. NMDA-receptor antagonist and morphine decrease CRPS-pain and cerebral pain representation. PAIN 2010;151:69–76.
[38]. Harden RN, Bruehl S, Perez RS, Birklein F, Marinus J, Maihofner C, Lubenow T, Buvanendran A, Mackey S, Graciosa J, Mogilevski M, Ramsden C, Chont M, Vatine JJ. Validation of proposed diagnostic criteria (the “Budapest criteria”) for complex regional pain syndrome. PAIN 2010;150:268–74.
[39]. Harden RN, Bruehl S, Perez RS, Birklein F, Marinus J, Maihofner C, Lubenow T, Buvanendran A, Mackey S, Graciosa J, Mogilevski M, Ramsden C, Schlereth T, Chont M, Vatine JJ. Development of a severity score for CRPS. PAIN 2010;151:870–6.
[40]. Hawley JS, Weiner WJ. Psychogenic dystonia and peripheral trauma. Neurology 2011;77:496–502.
[41]. He L, Uceyler N, Kramer HH, Colaco MN, Lu B, Birklein F, Sommer C. Methylprednisolone prevents nerve injury-induced hyperalgesia in neprilysin knockout mice. PAIN 2014;155:574–80.
[42]. Hühne K, Leis S, Schmelz M, Rautenstrauss B, Birklein F. A polymorphic locus in the intron 16 of the human angiotensin-converting enzyme (ACE) gene is not correlated with complex regional pain syndrome I (CRPS I). Eur J Pain 2004;8:221–5.
[43]. Ioannou LJ, Cameron PA, Gibson SJ, Gabbe BJ, Ponsford J, Jennings PA, Arnold CA, Gwini SM, Georgiou-Karistianis N, Giummarra MJ. Traumatic injury and perceived injustice: fault attributions matter in a “no-fault” compensation state. PLoS One 2017;12:e0178894.
[44]. Janicki PK, Alexander GM, Eckert J, Postula M, Schwartzman RJ. Analysis of common single nucleotide polymorphisms in complex regional pain syndrome: genome wide association study approach and pooled DNA strategy. Pain Med 2016;17:2344–52.
[45]. Jerrhag D, Englund M, Karlsson MK, Rosengren BE. Epidemiology and time trends of distal forearm fractures in adults—a study of 11.2 million person-years in Sweden. BMC Musculoskelet Disord 2017;18:240.
[46]. Johnson S, Hall J, Barnett S, Draper M, Derbyshire G, Haynes L, Rooney C, Cameron H, Moseley GL, de C Williams AC, McCabe C, Goebel A. Using graded motor imagery for complex regional pain syndrome in clinical practice: failure to improve pain. Eur J Pain 2012;16:550–61.
[47]. Kallmes DF, Comstock BA, Heagerty PJ, Turner JA, Wilson DJ, Diamond TH, Edwards R, Gray LA, Stout L, Owen S, Hollingworth W, Ghdoke B, Annesley-Williams DJ, Ralston SH, Jarvik JG. A randomized trial of vertebroplasty for osteoporotic spinal fractures. N Engl J Med 2009;361:569–79.
[48]. Kemler MA, de Vet HC, Barendse GA, van den Wildenberg FA, van Kleef M. Spinal cord stimulation for chronic reflex sympathetic dystrophy–five-year follow-up. N Engl J Med 2006;354:2394–6.
[49]. Klega A, Eberle T, Buchholz HG, Maus S, Maihofner C, Schreckenberger M, Birklein F. Central opioidergic neurotransmission in complex regional pain syndrome. Neurology 2010;75:129–36.
[50]. Kohr D, Singh P, Tschernatsch M, Kaps M, Pouokam E, Diener M, Kummer W, Birklein F, Vincent A, Goebel A, Wallukat G, Blaes F. Autoimmunity against the beta(2) adrenergic receptor and muscarinic-2 receptor in complex regional pain syndrome. PAIN 2011;152:2690–700.
[51]. Krumova EK, Frettloh J, Klauenberg S, Richter H, Wasner G, Maier C. Long-term skin temperature measurements—a practical diagnostic tool in complex regional pain syndrome. PAIN 2008;140:8–22.
[52]. Lee JY, Kim DK, Jung DW, Yang JY, Kim DY. Analysis of medical disputes regarding chronic pain management in the 2009–2016 period using the Korean Society of Anesthesiologists Database. Korean J Anesthesiol 2017;70:188–95.
[53]. Lenz M, Hoffken O, Stude P, Lissek S, Schwenkreis P, Reinersmann A, Frettloh J, Richter H, Tegenthoff M, Maier C. Bilateral somatosensory cortex disinhibition in complex regional pain syndrome type I. Neurology 2011;77:1096–101.
[54]. Lenz M, Uceyler N, Frettloh J, Hoffken O, Krumova EK, Lissek S, Reinersmann A, Sommer C, Stude P, Waaga-Gasser AM, Tegenthoff M, Maier C. Local cytokine changes in complex regional pain syndrome type I (CRPS I) resolve after 6 months. PAIN 2013;154:2142–9.
[55]. Maihofner C, Baron R, Decol R, Binder A, Birklein F, Deuschl G, Handwerker HO, Schattschneider J. The motor system shows adaptive changes in complex regional pain syndrome. Brain 2007;130:2671–87.
[56]. Maihofner C, Handwerker HO, Birklein F. Functional imaging of allodynia in complex regional pain syndrome. Neurology 2006;66:711–17.
[57]. Mainka T, Bischoff FS, Baron R, Krumova EK, Nicolas V, Pennekamp W, Treede RD, Vollert J, Westermann A, Maier C. Comparison of muscle and joint pressure-pain thresholds in patients with complex regional pain syndrome and upper limb pain of other origin. PAIN 2014;155:591–7.
[58]. Marinus J, Moseley GL, Birklein F, Baron R, Maihofner C, Kingery WS, van Hilten JJ. Clinical features and pathophysiology of complex regional pain syndrome. Lancet Neurol 2011;10:637–48.
[59]. McDonald MK, Tian Y, Qureshi RA, Gormley M, Ertel A, Gao R, Aradillas Lopez E, Alexander GM, Sacan A, Fortina P, Ajit SK. Functional significance of macrophage-derived exosomes in inflammation and pain. PAIN 2014;155:1527–39.
[60]. Michal M, Adler J, Reiner I, Wermke A, Ackermann T, Schlereth T, Birklein F. Association of neglect-like symptoms with anxiety, somatization, and depersonalization in complex regional pain syndrome. Pain Med 2017;18:764–72.
[61]. Mitchell SW, Morehouse GR, Keen WW. Gunshot wounds and other injuries of nerves. Philadelphia: JB Lippincott & Co., 1864.
[62]. Moseley GL. Graded motor imagery is effective for long-standing complex regional pain syndrome: a randomised controlled trial. PAIN 2004;108:192–8.
[63]. Moseley GL. Graded motor imagery for pathologic pain: a randomized controlled trial. Neurology 2006;67:2129–34.
[64]. Moseley GL, Gallace A, Iannetti GD. Spatially defined modulation of skin temperature and hand ownership of both hands in patients with unilateral complex regional pain syndrome. Brain 2012;135:3676–86.
[65]. Moseley GL, Herbert RD, Parsons T, Lucas S, Van Hilten JJ, Marinus J. Intense pain soon after wrist fracture strongly predicts who will develop complex regional pain syndrome: prospective cohort study. J Pain 2014;15:16–23.
[66]. Moseley GL, Zalucki N, Birklein F, Marinus J, van Hilten JJ, Luomajoki H. Thinking about movement hurts: the effect of motor imagery on pain and swelling in people with chronic arm pain. Arthritis Rheum 2008;59:623–31.
[67]. O'Connell NE, Wand BM, Gibson W, Carr DB, Birklein F, Stanton TR. Local anaesthetic sympathetic blockade for complex regional pain syndrome. Cochrane Database Syst Rev 2016;7:CD004598.
[68]. O'Connell NE, Wand BM, McAuley J, Marston L, Moseley GL. Interventions for treating pain and disability in adults with complex regional pain syndrome. Cochrane Database Syst Rev 2013;4:CD009416.
[69]. Opree A, Kress M. Involvement of the proinflammatory cytokines tumor necrosis factor-alpha, IL-1 beta, and IL-6 but not IL-8 in the development of heat hyperalgesia: effects on heat-evoked calcitonin gene-related peptide release from rat skin. J Neurosci 2000;20:6289–93.
[70]. Parisod E, Murray RF, Cousins MJ. Conversion disorder after implant of a spinal cord stimulator in a patient with a complex regional pain syndrome. Anesth Analg 2003;96:201–6, table of contents.
[71]. Paus R. Principles of hair cycle control. J Dermatol 1998;25:793–802.
[72]. Peltz E, Seifert F, Lanz S, Muller R, Maihofner C. Impaired hand size estimation in CRPS. J Pain 2011;12:1095–101.
[73]. Perez RS, Zuurmond WW, Bezemer PD, Kuik DJ, Van loenen AC, de Lange JJ, Zuidhof AJ. The treatment of complex regional pain syndrome type I with free radical scavengers: a randomized controlled study. PAIN 2003;102:297–307.
[74]. Peterlin BL, Rosso AL, Nair S, Young WB, Schwartzman RJ. Migraine may be a risk factor for the development of complex regional pain syndrome. Cephalalgia 2010;30:214–23.
[75]. Punt TD, Cooper L, Hey M, Johnson MI. Neglect-like symptoms in complex regional pain syndrome: learned nonuse by another name? PAIN 2013;154:200–3.
[76]. Roeckel LA, Le Coz GM, Gaveriaux-Ruff C, Simonin F. Opioid-induced hyperalgesia: cellular and molecular mechanisms. Neuroscience 2016;338:160–82.
[77]. Sandroni P, Benrud-Larson LM, McClelland RL, Low PA. Complex regional pain syndrome type I: incidence and prevalence in Olmsted county, a population-based study. PAIN 2003;103:199–207.
[78]. Sato J, Perl ER. Adrenergic excitation of cutaneous pain receptors induced by peripheral nerve injury. Science 1991;251:1608–10.
[79]. Schilder JC, van Dijk JG, Dressler D, Koelman JH, Marinus J, van Hilten JJ. Responsiveness to botulinum toxin type A in muscles of complex regional pain patients with tonic dystonia. J Neural Transm (Vienna) 2014;121:761–7.
[80]. Schlereth T, Dittmar JO, Seewald B, Birklein F. Peripheral amplification of sweating—a role for calcitonin gene-related peptide. J Physiol 2006;576:823–32.
[81]. Schrag A, Trimble M, Quinn N, Bhatia K. The syndrome of fixed dystonia: an evaluation of 103 patients. Brain 2004;127:2360–72.
[82]. Sigtermans MJ, van Hilten JJ, Bauer MC, Arbous MS, Marinus J, Sarton EY, Dahan A. Ketamine produces effective and long-term pain relief in patients with Complex Regional Pain Syndrome Type 1. PAIN 2009;145:304–11.
[83]. Singh G, Willen SN, Boswell MV, Janata JW, Chelimsky TC. The value of interdisciplinary pain management in complex regional pain syndrome type I: a prospective outcome study. Pain Physician 2004;7:203–9.
[84]. Speck V, Schlereth T, Birklein F, Maihofner C. Increased prevalence of posttraumatic stress disorder in CRPS. Eur J Pain 2017;21:466–73.
[85]. Speck V, Schlereth T, Birklein F, Maihofner C. Increased prevalence of posttraumatic stress disorder in CRPS. Eur J Pain 2017;21:466–73.
[86]. Stanton-Hicks M, Jänig W, Hassenbusch S, Haddox JD, Boas RA, Wilson PR. Reflex sympathetic dystrophy: changing concepts and taxonomy. PAIN 1995;63:127–33.
[87]. Sudeck P. Über die akute (reflektorische) Knochenatrophie nach Entzündungen und Verletzungen in den Extremitäten und ihre klinischen Erscheinungen. Fortschr Röntgenstr 1901;5:227–93.
[88]. Upadhyay J, Geber C, Hargreaves R, Birklein F, Borsook D. A critical evaluation of validity and utility of translational imaging in pain and analgesia: utilizing functional imaging to enhance the process. Neurosci Biobehav Rev 2017:S0149-7634(17)30206-3.
[89]. Urban PP, Solinski M, Best C, Rolke R, Hopf HC, Dieterich M. Different short-term modulation of cortical motor output to distal and proximal upper-limb muscles during painful sensory nerve stimulation. Muscle Nerve 2004;29:663–9.
[90]. van de Meent H, Oerlemans M, Bruggeman A, Klomp F, van Dongen R, Oostendorp R, Frolke JP. Safety of “pain exposure” physical therapy in patients with complex regional pain syndrome type 1. PAIN 2011;152:1431–8.
[91]. van de Vusse AC, Stomp-van den Berg SG, Kessels AH, Weber WE. Randomised controlled trial of gabapentin in complex regional pain syndrome type 1 [ISRCTN84121379]. BMC Neurol 2004;4:13.
[92]. van Hilten BJ, van de Beek WJ, Hoff JI, Voormolen JH, Delhaas EM. Intrathecal baclofen for the treatment of dystonia in patients with reflex sympathetic dystrophy. N Engl J Med 2000;343:625–30.
[93]. van Rooijen DE, Geraedts EJ, Marinus J, Jankovic J, van Hilten JJ. Peripheral trauma and movement disorders: a systematic review of reported cases. J Neurol Neurosurg Psychiatry 2011;82:892–8.
[94]. Veldman PHJM, Reynen HM, Arntz IE, Goris RJA. Signs and symptoms of reflex sympathetic dystrophy: prospective study of 829 patients. Lancet 1993;342:1012–16.
[95]. Wang L, Guo TZ, Wei T, Li WW, Shi X, Clark JD, Kingery WS. Bisphosphonates inhibit pain, bone loss, and inflammation in a rat tibia fracture model of complex regional pain syndrome. Anesth Analg 2016;123:1033–45.
[96]. Weber M, Birklein F. Complex regional pain syndrome: an actual survey. Expert RevNeurother 2001;1:100–9.
[97]. Weber M, Birklein F, Neundorfer B, Schmelz M. Facilitated neurogenic inflammation in complex regional pain syndrome. PAIN 2001;91:251–7.
[98]. Wehmeyer C, Pap T, Buckley CD, Naylor AJ. The role of stromal cells in inflammatory bone loss. Clin Exp Immunol 2017;189:1–11.
[99]. Williams AC, Eccleston C, Morley S. Psychological therapies for the management of chronic pain (excluding headache) in adults. Cochrane Database Syst Rev 2012;11:CD007407.
[100]. Winston P. Early treatment of acute complex regional pain syndrome after fracture or injury with prednisone: why is there a failure to treat? A case series. Pain Res Manag 2016;2016:7019196.
[101]. Wuppenhorst N, Maier C, Frettloh J, Pennekamp W, Nicolas V. Sensitivity and specificity of 3-phase bone scintigraphy in the diagnosis of complex regional pain syndrome of the upper extremity. Clin J Pain 2010;26:182–9.
[102]. Zuurmond WW, Langendijk PN, Bezemer PD, Brink HE, de Lange JJ, Van loenen AC. Treatment of acute reflex sympathetic dystrophy with DMSO 50% in a fatty cream. Acta Anaesthesiol Scand 1996;40:364–7.
Keywords:

Complex regional pain syndrome; Posttraumatic inflammation; Neuroplasticity; Central reorganisation; Treatment

© 2017 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of The International Association for the Study of Pain.